The present application relates to a microorganism in which an activity of erythronate-4-phosphate dehydrogenase is weakened; a method for producing O-phosphoserine, cysteine, or cysteine derivatives using the microorganism; a composition for producing O-phosphoserine comprising the microorganism; and the use of the microorganism in the production of O-phosphoserine, cysteine, and cysteine derivatives.

A method for converting a carbon source into serine includes: synthesizing a DNA sequence; implanting the DNA sequence into a plasmid, so that the plasmid includes gene sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; implanting the plasmid into cyanobacteria through an electroporation treatment, so as to obtain modified cyanobacteria; and providing the carbon source to the modified cyanobacteria, so that the modified cyanobacteria convert the carbon source into the serine.

Processes for producing L-cysteic acid along with uses for the same. The process includes providing a reaction of O-phospho-L-serine (OPS) with a salt of sulfurous acid (sulfite) and a cysteate synthase (CS enzyme) belonging to enzyme class EC 2.5.1.76 in a biotransformation. Where a concentration of OPS in a batch is at least 1 g/L and the CS enzyme is produced in an enzymatically active form by growth of the microorganism strain E. coli K12 JM105. The biotransformation is carried out under active pH control and the CS enzyme has an amino acid sequence specified in SEQ ID NO: 4 or an amino acid sequence homologous thereto. Where an amino acid sequence homologous to SEQ ID NO: 4 has a sequence identity of at least 50% in relation to SEQ ID NO: 4 and, at the same time, cysteate synthase enzyme activity.

A method for converting a carbon source into ethylene glycol includes: providing a plasmid, in which the plasmid includes gene sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6; implanting the plasmid into cyanobacteria through an electroporation treatment, so that modified cyanobacteria are obtained; and providing the carbon source to the modified cyanobacteria, so that the modified cyanobacteria convert the carbon source into the ethylene glycol.

The present disclosure relates to a novel YhhS variant and a method for producing O-phosphoserine, cysteine and a derivative of cysteine using the same.

An O-phosphoserine (OPS) export protein variant with increased O-phosphoserine exporting activity, and a method for producing O-phosphoserine, cysteine, and cysteine derivatives using the same. Also provided herein are O-phosphoserine-producing microorganisms, a polynucleotide encoding the O-phosphoserine export protein variant, and a vector containing the polynucleotide encoding the O-phosphoserine export protein variant.

Provided are a microorganism producing an L-amino acid or a precursor thereof, and a method of producing an L-amino acid or a precursor thereof using the microorganism.

Genetically engineered immune cells, which express at least two metabolism modulating polypeptides and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered immune cells for inhibiting cells expressing a target antigen in a subject in need thereof.

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.